Key Takeaways
- 18% revenue growth, margin leap: Consolidated revenue hit INR 91.9 cr with PAT margin jumping from 5% to 8.81% year-on-year for H1, driven by product demand and cost discipline.
- War disruption quantified: A temporary slowdown around the India-Pakistan conflict cost roughly INR 6 crores in top line and pushed the bottom line negative during that window, with delivery partners denying services and distribution hit.
- Bold margin roadmap laid out: Management guided PAT margin to 9% for the full year, 14-15% for FY27, and an 18-20% exit rate by FY28, powered by operating leverage, AI-driven data conversion, and ad cost savings of 100-200 bps.
- Asset-light model bending toward assets: A 300-bed Ayurveda hospital chain (INR 2 cr capex per 30 beds) and in-house capsule manufacturing are now firm commitments, though both are funded entirely through internal accruals with no equity dilution planned.
- What to watch next quarter: Whether the India Post receivables glitch fully resolves, the Blinkit quick-commerce test yields viable unit economics, and any tangible progress on the Ayush hospital approval process.
Revenue Engine & Disruptions
- Core growth intact: Standalone revenue grew 17% YoY to INR 88.35 cr on solid product demand and efficient delivery, with management calling H2 momentum "even more powerful" after a strong June comeback.
- War-linked slowdown: The company proactively slowed operations 15 days before the India-Pakistan conflict, and the disruption persisted 15 days after, costing ~INR 6 cr in lost revenue and a negative bottom line for that period as delivery partners refused service and distribution suffered.
- India Post glitch hit receivables: Trade receivables swelled because a software transformation at India Post stuck payments for at least 45 days; 80% has since been collected and the rest is expected in 10-15 days.
- Growth rate ambition: Current-year growth is tracking at 20-25%, with management stating 30-40% is achievable if pushed, and 40% is possible.
- Revenue vision stack: INR 200+ cr targeted for FY26 (described as "definitely in our control"), INR 300 cr by FY27 end, and INR 500+ cr as a longer-term aspiration driven by hospitals, AI-led low-ticket conversion, the US subsidiary, and international territories.
Chadha: "Sat Kartar has still just learned to start walking. There's a long way to go."
Margin Trajectory & Profitability Drivers
- PAT margin doubled in H1: PAT margin rose from 5% in H1 FY25 to 8.81% in H1 FY26, with EBITDA improving 200+ bps as a percentage of revenue through disciplined spending and operational excellence.
- Full-year target of 9%: Management expects to close FY26 at a 9% PAT margin, with a possibility of beating to 9-10% if H2 matches H1 performance.
- FY27 and FY28 roadmap: PAT margin is guided to 14-15% for FY27, reaching an 18-20% exit run rate by FY28 close, with the jump from 6% to 10% translating to more than 100% growth in basis points year-on-year.
- Three margin levers identified: Operating leverage from better infrastructure utilization, 100-200 bps of advertising cost savings, and an AI-driven model for better data analysis, churning, and conversion into sales.
- First-sale ROI model: The business is built so the first sale generates ROI, and the second, third, and fourth sales add to profit, with premium pricing justified because products sell a lifestyle rather than curing diseases.
Chadha: "I will not say 10%-11%, I will say, this jump is from 6%-9%. And yes, not only 6-9%, I will say 4%-6%, then 6-9%, then 12%-15%, and yes, 20% is also not far."
Hospital & Manufacturing Expansion
- 300-bed Ayurveda hospital plan: First phase of 30 beds targeted by Q1 FY27, scaling to 300 beds operational by Q4 FY27, with a gestation period to breakeven of 6-8 months per facility and capacity utilization ramping month-on-month from 10-50%.
- Hospital economics: Capex is INR 2 cr per 30-bed unit, entirely funded through internal accruals with no equity dilution planned. At 80-90% utilization and INR 10,000 per operational bed per day, the 300-bed chain could generate INR 100 cr in revenue at 25-30% EBITDA margins, which would be margin-accretive to the consolidated business.
- Location strategy: Initial rollout concentrated in the NCR region with 70-100 beds, then expanding beyond.
- Manufacturing unit live: An owned manufacturing facility is running with minimal capex (under INR 1 cr), serving as an R&D lab, though the company still believes in an asset-light model and contract manufacturing.
- Capsule manufacturing to scale: Management plans to manufacture at least 50% of capsules in-house, potentially starting Q1 FY27, with factory capacity already equipped for FY27 revenue projections and spare floors available for tablet expansion.
- Deliberate under-utilization: Capsule and powder manufacturing is kept at 50% capacity as contingency planning: if a supply chain stops while heavy market spending continues, a year's earnings could be lost in 15 days. The payback period on the facility at that utilization is around 18 months.
- No external supply planned: Management wants to concentrate only on Sat Kartar customers and investors for now, though supplying outside may be considered later to utilize the factory more.
AI, Digital & Brand Building
- AI rollout imminent: Beta testing is complete and the launch phase is starting, with the company describing itself as one of the first Ayurveda-led companies in India to deploy AI at scale for CRM intelligence, digital operations, and customer experience.
- Low-ticket data conversion: Currently only 10% of data is converted due to a high-ticket-size focus; AI will unlock the remaining 90% for a low-ticket-size product range, with the Plantomed acquisition (INR 1,300 ticket size) serving as a learning vehicle for that strategy without disturbing the core diabetes model (INR 2,500-2,600).
- Quick-commerce test live: Product Liv Muztang is listed on Blinkit in Maharashtra, with cost and revenue analysis now underway.
- Brand back-integration underway: Every product is being linked back to the Sat Kartar master brand, while individual products like "Addiction Killer" already command strong brand presence in South India (Tamil Nadu, Karnataka, Telangana, Andhra Pradesh).
- Competitive pressure anticipated: Management has already baked higher customer acquisition costs into its business plan, noting that Google, Meta, and other platforms will not spare advertisers, and both customer dilution and ad cost increases are mitigated.
Chadha: "Not really. Because this I have already anticipated into my business plan that yes, acquisition cost is going to be high. Google and Meta and other platforms are not going to spare any of the advertisers. They are first bothered about their pockets."
Customer Metrics & Definitions
- Repeat rate redefined: The red herring prospectus showed an 8.27% repeat rate calculated on a product basis (April-December 2024). The current 25% repeat rate is calculated on a customer basis, counting any repeat purchase by the same customer regardless of product. Management explained that some products, like a piles cure, should not have repeats if they work, so a product-based measure would logically be negative.
- Customer count not disclosed: When asked for the number of customers served in H1, management said the figure was not handy and offered a one-to-one discussion instead.
- No anchor-figure dependency: Management asserts the company is a "well-oiled machine" with systems governing themselves, and removal of any one name would not hit the company, citing Dabur as a comparable that thrives without an anchor figure.
Chadha: "The company is such a well-oiled machine, every system, is governing itself in such a way, that, if one name is removed, the company will not get a hit anywhere."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue target | INR 200+ cr | FY26 |
| Revenue target | INR 300 cr | FY27 end |
| Revenue aspiration | INR 500+ cr (product side only, excluding hospitals) | FY28 |
| PAT margin | 9% full-year (possible beat to 9-10%) | FY26 |
| PAT margin | 14-15% | FY27 |
| PAT margin exit rate | 18-20% | FY28 exit |
| Hospital beds operational | First 30 beds | Q1 FY27 |
| Hospital beds operational | Full 300 beds | Q4 FY27 |
| Hospital breakeven | 6-8 months gestation per facility | From operational date |
| In-house capsule manufacturing | At least 50% of capsules | Q1 FY27 (possible) |
| Equity dilution | None planned; entire hospital plan via internal accruals | Ongoing |
| Quick-commerce test | Liv Muztang on Blinkit in Maharashtra; cost/revenue analysis | Underway |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Consolidated revenue | ₹91.9 cr, +18% YoY (H1 FY26) |
| Standalone revenue | ₹88.35 cr, +17% YoY (H1 FY26) |
| PAT margin | 8.81% (H1 FY26), up from 5% in H1 FY25 |
| EBITDA margin improvement | 200+ bps YoY as a percentage of revenue (H1 FY26) |
| Top-line hit from May Indo-Pak disruption | ~₹6 cr |
| FY26 revenue target | ₹200+ cr |
| FY27 revenue target | ₹300 cr |
| FY28 revenue aspiration | ₹500 cr |
| FY27 PAT margin target | 12–15% |
| FY28 PAT margin target (exit run rate) | 18–20% |
| FY27 EBITDA margin guidance | ~15% |
| Average ticket size | ~₹3,300, up ~5% from ~₹3,000 earlier |
| Capsule and powder share of revenue | 50% |
| Own factory capacity utilization | 5–10% (started last month) |
| Hospital beds targeted by Q4 FY27 | 300 beds |
| Hospital first phase | 30 beds by Q1 FY27, capex ~₹2 cr |
| Hospital revenue potential (300 beds, 90% utilization) | ~₹100 cr (per an analyst's math) |
| Hospital EBITDA margin target | 25–30% |
| Advertisement cost outlook | flat to down 100–200 bps |
| Trade receivables recovery | 80% of stuck receivables received, rest in 10–15 days |